Toggle Main Menu Toggle Search

Open Access padlockePrints

Therapeutic Potential of Senolytics in Cardiovascular Disease

Lookup NU author(s): Emily Dookun, Dr Joao Passos, Professor Helen ArthurORCiD, Dr Gavin RichardsonORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Ageing is the biggest risk factor for impaired cardiovascular health, with cardiovascular disease being the leading cause of death in 40% of individuals over 65 years old. Ageing is associated with both an increased prevalence of cardiovascular disease including heart failure, coronary artery disease, and myocardial infarction. Furthermore, ageing is associated with a poorer prognosis to these diseases. Genetic models allowing the elimination of senescent cells revealed that an accumulation of senescence contributes to the pathophysiology of cardiovascular ageing and promotes the progression of cardiovascular disease through the expression of a proinflammatory and profibrotic senescence-associated secretory phenotype. These studies have resulted in an effort to identify pharmacological therapeutics that enable the specific elimination of senescent cells through apoptosis induction. These senescent cell apoptosis-inducing compounds are termed senolytics and their potential to ameliorate age-associated cardiovascular disease is the focus of this review.

Publication metadata

Author(s): Dookun E, Passos JF, Arthur HM, Richardson GD

Publication type: Article

Publication status: Published

Journal: Cardiovascular Drugs and Therapy

Year: 2022

Volume: 36

Pages: 187-196

Print publication date: 01/02/2022

Online publication date: 26/09/2020

Acceptance date: 03/09/2020

Date deposited: 19/10/2020

ISSN (print): 0920-3206

ISSN (electronic): 1573-7241

Publisher: Springer Nature


DOI: 10.1007/s10557-020-07075-w


Altmetrics provided by Altmetric


Funder referenceFunder name
PG/19/15/34269British Heart Foundation